Generate Biomedicines, Inc. SEC filings GENB

Generate Biomedicines, Inc. has 56 filings in SEC EDGAR's recent list, going back to Dec 23, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 26, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Generate Biomedicines, Inc. SEC filings
Form Description Filed Period
8-K Current report
Regulation FD disclosure
Aug 26, 2026 Aug 25, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 6, 2026 Aug 6, 2026
10-Q Quarterly report May 7, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
8-K Current report
Bylaw or fiscal year change
Mar 2, 2026 Feb 26, 2026
S-8 Employee stock plan registration Feb 27, 2026 —
424B4 Prospectus Feb 27, 2026 —
EFFECT Filing Feb 26, 2026 —
CERT Filing Feb 26, 2026 —
8-A12B Filing Feb 24, 2026 —
S-1/A Amended registration statement Feb 23, 2026 —
S-1/A Amended registration statement Feb 13, 2026 —
S-1 Registration statement Feb 4, 2026 —
DRS Filing Dec 23, 2025 —

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GENB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Somerville, MA
SEC filer status
, Emerging growth company
SEC CIK
2100782

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.